Cell Model for Testing Pharmaceuticals Targeting Human PD-L1.

Area of Science:

• Biotechnology
• Immunology
• Oncology

Background:

• The development of targeted therapies against programmed death-ligand 1 (PD-L1) is crucial for cancer treatment.
• Existing models for evaluating anti-PD-L1 agents require sophisticated infrastructure or lack comprehensive testing capabilities.

Purpose of the Study:

• To create and validate a genetically engineered cell model for assessing the specificity of anti-human PD-L1 therapeutic and diagnostic agents.
• To establish a robust platform for both in vitro and in vivo evaluation of PD-L1 targeting agents.

Main Methods:

• Genetically modified murine CT26 carcinoma cells (CT26-PD-L1) were created to express human PD-L1.
• PD-L1 expression was confirmed using real-time PCR and flow cytometry.
• The model was tested using radioisotope-conjugated anti-PD-L1 nanobodies for in vitro and in vivo specificity and internalization studies.

Main Results:

• The CT26-PD-L1 cell line successfully expressed human PD-L1 and formed tumors in mice.
• In vivo studies demonstrated specific accumulation of radioimmunoconjugates in CT26-PD-L1 tumors but not in control CT26 tumors.
• In vitro experiments confirmed internalization of anti-PD-L1 nanobodies by CT26-PD-L1 cells.

Conclusions:

• The developed CT26-PD-L1 cell model is suitable for in vitro and in vivo testing of anti-human PD-L1 agent specificity.
• This model provides a valuable tool for preclinical evaluation of novel PD-L1 targeted therapeutics and diagnostics.
• The model facilitates confirmation of pharmaceutical specificity and quantification of target-binding fractions in a single assay.